Literature DB >> 10667612

Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.

M Laruelle1, A Abi-Dargham.   

Abstract

Abnormalities of dopamine function in schizophrenia are suggested by the common antidopaminergic properties of antipsychotic medications. However, direct evidence of a hyperdopaminergic state in schizophrenia has been difficult to demonstrate, given the difficulty of measuring dopamine transmission in the living human brain. This situation is rapidly changing. Recent developments in positron emission tomography and single-photon emission tomographic techniques enabled measurement of acute fluctuation of synaptic dopamine in the vicinity of D2 receptors. Using this technique, we, and others, measured the increase in dopamine transmission following acute amphetamine challenge in untreated patients with schizophrenia and matched healthy subjects. Following a brief overview of these new brain imaging techniques, the main results derived with this method in patients with schizophrenia are described: (1) amphetamine-induced dopamine release is elevated in patients with schizophrenia, supporting the idea that schizophrenia is associated with dysregulation of dopamine transmission; (2) following amphetamine, hyperactivity of dopamine transmission is associated with activation of psychotic symptomatology; (3) this dysregulation of dopamine release is not a long-term consequence of previous neuroleptic treatment, and is detected in never-medicated patients experiencing a first episode of the illness; and (4) in contrast, this exaggerated response of the dopamine system to amphetamine exposure is not detected in patients studied during a period of illness stabilization, suggesting that the hyperdopaminergic state associated with schizophrenia fluctuates over time. In conclusion, a hyperdopaminergic state might be present in schizophrenia during the initial episode and subsequent relapses, but not during periods of remission. This finding has important consequences for the development of new treatment strategies for the remission phase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10667612     DOI: 10.1177/026988119901300405

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  150 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

3.  Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony.

Authors:  Kafui Dzirasa; H Westley Phillips; Tatyana D Sotnikova; Ali Salahpour; Sunil Kumar; Raul R Gainetdinov; Marc G Caron; Miguel A L Nicolelis
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 4.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 5.  Developmental pathology, dopamine, stress and schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Int J Dev Neurosci       Date:  2010-08-19       Impact factor: 2.457

6.  Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Authors:  Oliver D Howes; Paul Shotbolt; Michael Bloomfield; Kirstin Daalman; Arsime Demjaha; Kelly M J Diederen; Kemal Ibrahim; Euitae Kim; Philip McGuire; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

Review 7.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.

Authors:  Li Chen; Stephanie M Perez; Daniel J Lodge
Journal:  Dev Neurobiol       Date:  2014-03-03       Impact factor: 3.964

10.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.